Kenvue (KVUE) Stock Price, News & Analysis

Company Overview

Kenvue Inc. is a global consumer health company that develops, markets and sells products designed to support everyday health and personal care. Its portfolio spans over-the-counter medicines, skin health and beauty, essential health products, and baby and family care.

The company’s brands include Tylenol, Motrin, Zyrtec and Benadryl in self-care; Neutrogena, Aveeno and Clean & Clear in skin health and beauty; Listerine in oral care; and Johnson’s and Band-Aid in baby care and essential health. Kenvue products are sold through retailers, pharmacies, e-commerce channels and other distribution networks in markets around the world.

Kenvue was formed from the consumer health business of Johnson & Johnson and became a publicly traded company on the New York Stock Exchange in 2023. Johnson & Johnson completed the separation of Kenvue as an independent company in 2024. Kenvue is headquartered in Skillman, New Jersey, and is led by Chief Executive Officer Thibaut Mongon.

Key Stats

• Today's Range: $17.71 to $17.88
• 50-Day Range: $17.68 to $19.78
• 52-Week Range: $14.02 to $20.13
• Volume: 2.58 million shs
• Average Volume: 27.87 million shs
• Market Capitalization: $34.01 billion
• P/E Ratio: 20.37
• Dividend Yield: 4.74%
• Price Target: $19.27
• Consensus Rating: Hold

Kenvue Stock Analysis - MarketRank™

Kenvue scored higher than 68% of companies evaluated by MarketBeat, and ranked 76th out of 171 stocks in the consumer staples sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.6 / 5
• Analyst Rating: Hold

Consensus Rating

Kenvue has received a consensus rating of Hold. The company's average rating score is 2.21, and is based on no strong buy ratings, 3 buy ratings, 11 hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for Kenvue is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Kenvue has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 7.89%

Earnings Growth

Earnings for Kenvue are expected to grow by 7.89% in the coming year, from $1.14 to $1.23 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Kenvue is 20.32, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.99.

Price to Earnings Ratio vs. Sector

The P/E ratio of Kenvue is 20.32, which means that it is trading at a more expensive P/E ratio than the Consumer Staples sector average P/E ratio of about 14.16.

Price to Earnings Growth Ratio

Kenvue has a PEG Ratio of 1.64. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Kenvue has a P/B Ratio of 3.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.82% of the float of Kenvue has been sold short.

Short Interest Ratio / Days to Cover

Kenvue has a short interest ratio ("days to cover") of 3.35, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Kenvue has recently increased by 36.68%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Leadership

Kenvue is a leading dividend payer. It pays a dividend yield of 4.70%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

Kenvue has only been increasing its dividend for 1 years.

Dividend Coverage

The dividend payout ratio of Kenvue is 96.55%. Payout ratios above 75% are not desirable because they may not be sustainable.

Dividend Sustainability

Based on earnings estimates, Kenvue will have a dividend payout ratio of 68.29% next year. This indicates that Kenvue will be able to sustain or increase its dividend.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.63

News Sentiment

Kenvue has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Consumer Staples companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for Kenvue this week, compared to 7 articles on an average week.

Search Interest

17 people have searched for KVUE on MarketBeat in the last 30 days. This is an increase of 31% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added Kenvue to their MarketBeat watchlist in the last 30 days. This is a decrease of -57% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Kenvue insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.59% of the stock of Kenvue is held by insiders.

Percentage Held by Institutions

97.64% of the stock of Kenvue is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Record date for 8/26 Dividend: 8/12/2026
• Ex-Dividend for 8/26 Dividend: 8/12/2026
• Dividend Payable: 8/26/2026
• Record date for 10/2 Dividend: 9/21/2026
• Ex-Dividend for 10/2 Dividend: 9/21/2026
• Today: 9/24/2026
• Dividend Payable: 10/02/2026
• Next Earnings (Estimated): 11/02/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Consumer Staples
• Industry: Personal Care Products
• Sub-Industry: Personal Care Products
• Current Symbol: NYSE:KVUE
• CIK: 1944048
• Web: www.kenvue.com
• Phone: (908) 874-1200
• Fax: N/A
• Employees: 22,000
• Year Founded: 2023

Price Target and Rating

• Average Price Target for Kenvue: $19.27
• High Price Target: $22.00
• Low Price Target: $18.00
• Potential Upside/Downside: +8.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.21
• Research Coverage: 14 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.87
• Trailing P/E Ratio: 20.42
• Forward P/E Ratio: 15.55
• P/E Growth: 1.64
• Net Income: $1.47 billion
• Net Margins: 10.76%
• Pretax Margin: 14.43%
• Return on Equity: 21.22%
• Return on Assets: 8.37%

Debt

• Debt-to-Equity Ratio: 0.67
• Current Ratio: 1.01
• Quick Ratio: 0.71

Sales & Book Value

• Annual Sales: $15.12 billion
• Price / Sales: 2.25
• Cash Flow: $1.37 per share
• Price / Cash Flow: 12.95
• Book Value: $5.62 per share
• Price / Book: 3.15

Miscellaneous

• Outstanding Shares: 1,920,770,000
• Free Float: 1,890,234,000
• Market Cap: $34.05 billion
• Optionable: Optionable
• Beta: 0.46